Connexion
Inscription
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
UCB
UCB
| Temps réel Euronext Bruxelles - 17:35:13 24/03/2023 | |
| 78.98 EUR | +0.13% |
Métier
| Santé | ||||
 | Recherche pharmaceutique et médicale | |||
| Produits pharmaceutiques | |||
| Produits pharmaceutiques | |||
| Biopharmacies | |||
UCB est une société biopharmaceutique qui se consacre à la recherche et au développement de nouveaux médicaments et de solutions innovantes destinés aux personnes atteintes de maladies graves du système nerveux central ou immunitaire.
Nombre d'employés : 8 703 personnes.
Nombre d'employés : 8 703 personnes.
Ventes par activité
| 2021 | 2022 | ||||
| Biopharmaceuticals | 5 471.00 | 94.7% | 5 140.00 | 93.2% | |
| EUR en Millions | |||||
Ventes par région
| 2021 | 2022 | ||||
| United States | 2 888.00 | 50% | 2 902.00 | 52.6% | |
| Other Countries | 429.00 | 7.4% | 507.00 | 9.2% | |
| Europe- Other (excluding Belgium) | 331.00 | 5.7% | 348.00 | 6.3% | |
| Germany | 335.00 | 5.8% | 330.00 | 6% | |
| Japan | 561.00 | 9.7% | 324.00 | 5.9% | |
| Spain | 202.00 | 3.5% | 213.00 | 3.9% | |
| France (including French Territories) | 172.00 | 3% | 169.00 | 3.1% | |
| Global | 57.00 | 1% | -167.00 | -3% | |
| China | 140.00 | 2.4% | 159.00 | 2.9% | |
| Italy | 159.00 | 2.8% | 154.00 | 2.8% | |
| United Kingdom and Ireland | 150.00 | 2.6% | 151.00 | 2.7% | |
| Belgium | 47.00 | 0.8% | 49.00 | 0.9% | |
| EUR en Millions | |||||
Dirigeants
| Nom | Titre |
| Jean-Christophe Tellier | Chief Executive Officer & Executive Director |
| Sandrine Dufour | Chief Financial Officer & Executive Vice President |
| Jonathan M. Peacock | Chairman |
| Iris Löw-Friedrich | Chief Medical Officer, EVP & Head-Development |
| Dhavalkumar Patel | Chief Scientific Officer & Executive VP |
| Herman de Prins | Chief Information Officer |
| Kirsten Lund Jurgensen | Executive VP, Head-Supply & Technology Unit |
| Albrecht de Graeve | Independent Director |
| Ulf Arne Wiinberg | Independent Director |
| Pierre L. Gurdjian | Independent Director |
| Actionnaires |
| Nom | Actions | % |
| Financière de Tubize SA | 68 333 981 | 35,1% |
| Wellington Management Co. LLP | 20 068 998 | 10,3% |
| Fidelity Management & Research Co. LLC | 6 321 746 | 3,25% |
| UCB SA | 5 331 781 | 2,74% |
| The Vanguard Group, Inc. | 3 387 715 | 1,74% |
| Norges Bank Investment Management | 3 014 393 | 1,55% |
| Fideuram Asset Management (Ireland) DAC | 2 855 469 | 1,47% |
| Amundi Asset Management SA (Investment Management) | 2 729 498 | 1,40% |
| Baillie Gifford & Co. | 1 937 869 | 1,00% |
| BlackRock Advisors (UK) Ltd. | 1 577 365 | 0,81% |
Coordonnées société
Allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
BE-1070 Bruxelles, Bruxelles-Capitale
Téléphone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : https://www.ucb.com/
Places et indices
| - Compartiment A |
| - BEL 20 / BEL ESG, Euronext 100, PEA, STOXX Europe 600 |
Codes boursiers
| - Code Bloomberg : | UCB:BB |
| - Code Reuters : | UCB.BR |
Secteur Biopharmacies
| Var. 1janv | Capi. (M$) | ||
 | |||
| UCB SA | 8.37% | 16 289 | |
| |||
| CSL LIMITED | 0.15% | 93 458 | |
| SAMSUNG BIOLOGICS CO.,LTD. | -1.34% | 44 439 | |
| BIOGEN INC. | -4.24% | 38 313 | |
| WUXI BIOLOGICS (CAYMAN) INC. | -15.29% | 27 312 | |
| CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. | -0.36% | 20 262 | |
| BIOMARIN PHARMACEUTICAL INC. | -12.93% | 16 808 | |
| UCB | 7.23% | 16 289 | |
| BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. | -6.24% | 16 012 | |
| WALVAX BIOTECHNOLOGY CO., LTD. | -5.23% | 8 586 | |
| CELLTRION HEALTHCARE CO., LTD. | 13.62% | 8 113 | |
| BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED | -18.66% | 7 772 | |
| INNOVENT BIOLOGICS, INC. | 16.42% | 7 624 | |
| APELLIS PHARMACEUTICALS, INC. | 22.26% | 7 289 | |
| SWEDISH ORPHAN BIOVITRUM AB (PUBL) | 13.40% | 7 059 | |
| SHANGHAI JUNSHI BIOSCIENCES CO., LTD. | -41.34% | 6 322 | |
| HUALAN BIOLOGICAL ENGINEERING INC. | -2.17% | 5 998 | |
| BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. | 1.73% | 5 971 | |
| GRIFOLS, S.A. | -16.27% | 5 951 | |
| SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. | 3.46% | 5 301 | |
| SK BIOSCIENCE CO.,LTD. | -3.13% | 4 211 | |
Portefeuille de Marques
